SciELO - Scientific Electronic Library Online

 
vol.113 número2Esferocitosis hereditaria: Revisión. Parte II. Manifestaciones clínicas, evolución, complicaciones y tratamiento índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Archivos argentinos de pediatría

versión impresa ISSN 0325-0075

Resumen

COMITE DE NUTRICION. Consensus on management of dyslipidemia in pediatrics. Arch. argent. pediatr. [online]. 2015, vol.113, n.2, pp.177-187. ISSN 0325-0075.  http://dx.doi.org/10.5546/aap.2015.177.

This document is intended for pediatricians, family, nutritionists and others. It aimed to convey the guidelines for early diagnosis and treatment of dyslipidemia in children and sensitize the pediatrician to the prevention of cardiovascular disease in adults. Atherosclerosis is a gradual process that begins in childhood and dyslipidemia belongs to the group of risk factors that accelerate their evolution. Universal screening for dyslipidemia at 6 years and 17 years is proposed; selective screening after 2 years is recommended if there are risk factors or predisposing disease. Assay of total cholesterol, LDL, HDL and triglycerides is recommended, prior fasting. Treatment of dyslipidemia in children aims to reduce the risk of premature cardiovascular events in the case of hypercholesterolemia, and decreasing the risk of pancreatitis in the case of severe hypertriglyceridemia. The pediatrician should address screening, diagnosis and implementation of lipid-lowering measures. Patients with higher levels should be referred to specialists with expertise in drug therapy.

Palabras clave : Dyslipidemias; Hypercholesterolemia; Hypertriglyceridemia; Screening; Treatment.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons